5 news items
Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
APDN
MRVI
20 Jun 24
diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing
TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center
MRVI
13 May 24
and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics
Where Maravai LifeSciences Stands With Analysts
MRVI
9 May 24
, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing
TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production
MRVI
18 Apr 24
to ensuring the safety and efficacy of this new class of medicines for patients."
Company and site leadership
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024
MRVI
10 Apr 24
of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene
- Prev
- 1
- Next